Literature DB >> 18642631

Gamma knife radiosurgery for medically refractory idiopathic trigeminal neuralgia.

J H Kang1, Y S Yoon, D W Kang, S S Chung, J W Chang.   

Abstract

Gamma knife radiosurgery (GKS) has been generally considered as a viable therapeutic option for the management of medically refractory idiopathic trigeminal neuralgia (TN). We reviewed our experience with GKS in patients with TN. Between Feb 1996 and May 2006, 77 patients with medical refractory idiopathic TN were treated using GKS. Thirty-six patients who had undergone other previous procedures, previous GKS, or had brain stem lesion, atypical symptoms, were excluded from this study. Pain improvement was achieved in 38 of the patients with TN (pain response rate 92.7%). Twenty-three patients were pain free and 15 had reduced pain. There were no serious complications. We think that GKS is an effective treatment option for patients with medical refractory idiopathic TN.

Entities:  

Mesh:

Year:  2008        PMID: 18642631     DOI: 10.1007/978-3-211-78205-7_6

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  4 in total

1.  Current gamma knife treatment for ophthalmic branch of primary trigeminal neuralgia.

Authors:  Guo-Yong Shan; Hao-Fang Liang; Jian-Hua Zhang
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

2.  Clinical outcomes of gamma knife radiosurgery in the treatment of patients with trigeminal neuralgia.

Authors:  Ameer L Elaimy; Peter W Hanson; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Robert K Fairbanks; Barton S Cooke; Sudheer R Thumma; Christopher M Lee
Journal:  Int J Otolaryngol       Date:  2011-10-25

Review 3.  Treatment Outcomes in Trigeminal Neuralgia-A Systematic Review of Domains, Dimensions and Measures.

Authors:  Carolina Venda Nova; Joanna M Zakrzewska; Sarah R Baker; Richeal Ni Riordain
Journal:  World Neurosurg X       Date:  2020-01-27

Review 4.  Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view.

Authors:  Jan Vesper; B Bölke; C Wille; P A Gerber; C Matuschek; M Peiper; H J Steiger; W Budach; G Lammering
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.